The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 29, 2020

Filed:

Sep. 13, 2018
Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Nathanael Gray, Boston, MA (US);

Tinghu Zhang, Brookline, MA (US);

Nicholas Paul Kwiatkowski, Brookline, MA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 403/04 (2006.01); A61K 31/635 (2006.01); A61K 31/506 (2006.01); C07D 401/04 (2006.01); C07D 471/04 (2006.01); A61K 45/06 (2006.01); A61K 31/4439 (2006.01); C07D 417/04 (2006.01); C07D 513/04 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C07D 403/04 (2013.01); A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 513/04 (2013.01); A61K 2300/00 (2013.01); G01N 33/5011 (2013.01);
Abstract

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.


Find Patent Forward Citations

Loading…